Sana Biotechnology, Inc. Goodwill and Intangible Asset Impairment
Sana Biotechnology, Inc. (SANA) reported Goodwill and Intangible Asset Impairment of $0 for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-08.
Discontinued › Operating Expenses
us-gaap:GoodwillAndIntangibleAssetImpairment · last filed 2021-11-08
- Sana Biotechnology, Inc. goodwill and intangible asset impairment for the quarter ending 2021-09-30 was $0.00.
- Sana Biotechnology, Inc. goodwill and intangible asset impairment for the quarter ending 2021-06-30 was $0.00.
- Sana Biotechnology, Inc. goodwill and intangible asset impairment for the quarter ending 2021-03-31 was $0.00.
| Period end | Goodwill and Intangible Asset Impairment 3 month | Goodwill and Intangible Asset Impairment 6 month | Goodwill and Intangible Asset Impairment 9 month | Goodwill and Intangible Asset Impairment 11 month | Goodwill and Intangible Asset Impairment 12 month |
|---|---|---|---|---|---|
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $0.00 derived: sum of 2 quarters · filed 2021-11-08 | $0.00 10-Q · filed 2021-11-08 | ||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $0.00 10-Q · filed 2021-08-04 | |||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-05 | ||||
| 2020-12-31 | $0.00 10-Q · filed 2021-11-08 | ||||
| 2019-12-31 | $0.00 10-Q · filed 2021-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |